An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Clinical trial NCT03094429 · RECRUITING

Trial details

NCT number

NCT03094429

Sponsor

SyneuRx International (Taiwan) Corp

Status

RECRUITING

Phase

Phase 2, Phase 3

Study type

INTERVENTIONAL

Start date

2017-03-29

Primary completion

2026-09-30

Enrollment

287

View on ClinicalTrials.gov